# Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients

> **NCT00229749** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** AVI-4065 Injection

## Key facts

- **NCT ID:** NCT00229749
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2006-10
- **Final completion:** 2007-01
- **Target enrollment:** 80 (ESTIMATED)
- **Why stopped:** Limited viral load reduction in HCV subjects
- **Last updated:** 2008-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00229749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00229749, "Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00229749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*